Skip to main content

Harmony Biosciences Holdings Inc

For the period ended Dec 31, 2024. Filed Feb 25, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 25, 2025

HRMY$33.55-0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Operations and Comprehensive Income (Loss

HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (In thousands, except share and per share data)

​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Year Ended December 31,
​ · 2024 · 2023 · ​ · 2022
Net product revenue​$714,734​$582,022​$437,855
Cost of product sold​156,815​121,236​83,481
Gross profit​557,919​460,786​354,374
Operating expenses:​​​
Research and development​145,825​76,063​70,886
Sales and marketing​110,916​97,404​79,285
General and administrative​110,352​95,289​84,017
Total operating expenses​367,093​268,756​234,188
Operating income​190,826​192,030​120,186
Loss on debt extinguishment​—​(9,766)​—
Other (expense) income, net​(68)​159​169
Interest expense​​(17,496)​(23,757)​(18,795)
Interest income​18,542​14,730​3,126
Income before income taxes​191,804​173,396​104,686
Income tax expense​(46,311)​(44,543)​76,782
Net income​$145,493​$128,853​$181,468
Unrealized (loss) income on investments​64​153​(151)
Comprehensive income​$145,557​$129,006​$181,317
EARNINGS PER SHARE:​​​
Basic​$2.56​$2.17​$3.07
Diluted​$2.51​$2.13​$2.97
Weighted average number of shares of common stock - basic​56,885,455​59,469,648​59,173,121
Weighted average number of shares of common stock - diluted​57,869,915​60,372,397​61,097,045

HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.